单纯疱疹病毒引发酶 - 解旋酶抑制剂BAY 57 - 1293具有强大的体内抗病毒活性。
Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293.
作者信息
Betz Ulrich A K, Fischer Rüdiger, Kleymann Gerald, Hendrix Martin, Rübsamen-Waigmann Helga
机构信息
Bayer AG, Pharma Research Antiinfectives, Wuppertal, Germany.
出版信息
Antimicrob Agents Chemother. 2002 Jun;46(6):1766-72. doi: 10.1128/AAC.46.6.1766-1772.2002.
Abstract
BAY 57-1293 belongs to a new class of antiviral compounds and inhibits replication of herpes simplex virus (HSV) type 1 and type 2 in the nanomolar range in vitro by abrogating the enzymatic activity of the viral primase-helicase complex. In various rodent models of HSV infection the antiviral activity of BAY 57-1293 in vivo was found to be superior compared to all compounds currently used to treat HSV infections. The compound shows profound antiviral activity in murine and rat lethal challenge models of disseminated herpes, in a murine zosteriform spread model of cutaneous disease, and in a murine ocular herpes model. It is active in parenteral, oral, and topical formulations. BAY 57-1293 continued to demonstrate efficacy when the onset of treatment was initiated after symptoms of herpetic disease were already apparent.
摘要
BAY 57-1293属于一类新型抗病毒化合物，在体外通过消除病毒引发酶-解旋酶复合物的酶活性，在纳摩尔范围内抑制1型和2型单纯疱疹病毒（HSV）的复制。在各种HSV感染的啮齿动物模型中，发现BAY 57-1293在体内的抗病毒活性优于目前用于治疗HSV感染的所有化合物。该化合物在播散性疱疹的小鼠和大鼠致死性攻击模型、皮肤疾病的小鼠带状疱疹样扩散模型以及小鼠眼部疱疹模型中显示出强大的抗病毒活性。它在肠胃外、口服和局部制剂中均有活性。当在疱疹疾病症状已经明显后开始治疗时，BAY 57-1293仍继续显示出疗效。
相似文献
1
Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293.单纯疱疹病毒引发酶 - 解旋酶抑制剂BAY 57 - 1293具有强大的体内抗病毒活性。
Antimicrob Agents Chemother. 2002 Jun;46(6):1766-72. doi: 10.1128/AAC.46.6.1766-1772.2002.
2
Helicase primase: targeting the Achilles heel of herpes simplex viruses.解旋酶引发酶：靶向单纯疱疹病毒的阿喀琉斯之踵。
Antivir Chem Chemother. 2004 May;15(3):135-40. doi: 10.1177/095632020401500303.
3
Pharmacokinetics-pharmacodynamics of the helicase-primase inhibitor pritelivir following treatment of wild-type or pritelivir-resistant virus infection in a murine herpes simplex virus 1 infection model.在小鼠单纯疱疹病毒1感染模型中，解旋酶-引发酶抑制剂普瑞替韦治疗野生型或普瑞替韦耐药病毒感染后的药代动力学-药效学研究
Antimicrob Agents Chemother. 2014 Jul;58(7):3843-52. doi: 10.1128/AAC.02641-14. Epub 2014 Apr 21.
4
The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1.解旋酶引发酶抑制剂BAY 57-1293在感染1型单纯疱疹病毒的BALB/c小鼠中显示出优于泛昔洛韦的强效治疗性抗病毒活性。
Antiviral Res. 2007 Jul;75(1):30-5. doi: 10.1016/j.antiviral.2006.11.006. Epub 2006 Dec 11.
5
Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.单纯疱疹病毒解旋酶-引发酶抑制剂在人类疾病的动物模型中具有活性。
Nat Med. 2002 Apr;8(4):386-91. doi: 10.1038/nm0402-386.
6
Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease.解旋酶-引发酶抑制剂BAY 57-1293在人类生殖器疱疹疾病豚鼠模型中对疱疹感染和潜伏的卓越疗效。
Antivir Chem Chemother. 2007;18(1):35-48. doi: 10.1177/095632020701800104.
7
Helicase-primase inhibitors for herpes simplex virus: looking to the future of non-nucleoside inhibitors for treating herpes virus infections.疱疹单纯病毒的解旋酶-引发酶抑制剂：着眼于治疗疱疹病毒感染的非核苷抑制剂的未来。
Future Med Chem. 2014 Jan;6(1):45-55. doi: 10.4155/fmc.13.192.
8
Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model.解旋酶引物酶抑制剂（HPIs）在感染小鼠模型中对治疗人类单纯疱疹病毒（HSV）疾病有效。
Antiviral Res. 2021 Nov;195:105190. doi: 10.1016/j.antiviral.2021.105190. Epub 2021 Oct 16.
9
The helicase-primase inhibitor BAY 57-1293 reduces the Alzheimer's disease-related molecules induced by herpes simplex virus type 1.解旋酶-引发酶抑制剂 BAY 57-1293 降低单纯疱疹病毒 1 诱导的阿尔茨海默病相关分子。
Antiviral Res. 2013 Sep;99(3):401-4. doi: 10.1016/j.antiviral.2013.07.003. Epub 2013 Jul 16.
10
Efficacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection.解旋酶-引发酶抑制剂在单纯疱疹病毒1型眼部感染动物模型中的疗效。
J Ocul Pharmacol Ther. 2008 Feb;24(1):34-42. doi: 10.1089/jop.2007.0084.
引用本文的文献
1
Identification of potent HSV antivirals using 3D bioprinted human skin equivalents.使用3D生物打印的人体皮肤等效物鉴定强效单纯疱疹病毒抗病毒药物。
bioRxiv. 2024 Dec 9:2024.12.04.626896. doi: 10.1101/2024.12.04.626896.
2
A Screening Study Identified Decitabine as an Inhibitor of Equid Herpesvirus 4 That Enhances the Innate Antiviral Response.一项筛选研究发现地西他滨是抑制马疱疹病毒 4 的抑制剂，可增强先天抗病毒反应。
Viruses. 2024 May 8;16(5):746. doi: 10.3390/v16050746.
3
Salvage Treatment of Refractory HSV Oral Lesions with Pritelivir in Allogeneic Hematopoietic Cell Transplant Recipients.异基因造血细胞移植受者普瑞巴林治疗难治性单纯疱疹病毒口腔病变。
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0173222. doi: 10.1128/aac.01732-22. Epub 2023 Mar 27.
4
An Insight into Current Treatment Strategies, Their Limitations, and Ongoing Developments in Vaccine Technologies against Herpes Simplex Infections.深入了解针对单纯疱疹感染的当前治疗策略、其局限性以及疫苗技术的最新进展。
Vaccines (Basel). 2023 Jan 17;11(2):206. doi: 10.3390/vaccines11020206.
5
Complete and Prolonged Inhibition of Herpes Simplex Virus Type 1 Infection In Vitro by CRISPR/Cas9 and CRISPR/CasX Systems.CRISPR/Cas9 和 CRISPR/CasX 系统体外完全和持续抑制单纯疱疹病毒 1 感染。
Int J Mol Sci. 2022 Nov 27;23(23):14847. doi: 10.3390/ijms232314847.
6
Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections.普瑞巴林的发现、化学结构和临床前开发：一种治疗阿昔洛韦耐药单纯疱疹病毒感染的新选择。
J Med Chem. 2022 Oct 27;65(20):13614-13628. doi: 10.1021/acs.jmedchem.2c00668. Epub 2022 Oct 6.
7
Peptide Inhibitor of Complement C1, RLS-0071, Reduces Zosteriform Spread of Herpes Simplex Virus Type 1 Skin Infection and Promotes Survival in Infected Mice.补体 C1 肽抑制剂 RLS-0071 减少单纯疱疹病毒 1 型皮肤感染的带状疱疹样扩散并促进感染小鼠的存活。
Viruses. 2021 Jul 22;13(8):1422. doi: 10.3390/v13081422.
8
The three-component helicase/primase complex of herpes simplex virus-1.单纯疱疹病毒-1 的三组分解旋酶/引发酶复合物。
Open Biol. 2021 Jun;11(6):210011. doi: 10.1098/rsob.210011. Epub 2021 Jun 9.
9
Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase.泊沙康唑和格拉瑞韦作为 SARS-CoV-2 解旋酶抑制剂的再利用潜力。
Sci Rep. 2021 May 13;11(1):10290. doi: 10.1038/s41598-021-89724-0.
10
The Use of Antimicrobial and Antiviral Drugs in Alzheimer's Disease.抗微生物和抗病毒药物在阿尔茨海默病中的应用。
Int J Mol Sci. 2020 Jul 12;21(14):4920. doi: 10.3390/ijms21144920.
本文引用的文献
1
New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease.新型解旋酶-引发酶抑制剂作为治疗单纯疱疹疾病的候选药物。
Nat Med. 2002 Apr;8(4):392-8. doi: 10.1038/nm0402-392.
2
Intravenous infusion of cereport increases uptake and efficacy of acyclovir in herpes simplex virus-infected rat brains.静脉输注 Cereport 可增加阿昔洛韦在单纯疱疹病毒感染大鼠脑中的摄取及疗效。
Antimicrob Agents Chemother. 2001 Aug;45(8):2316-23. doi: 10.1128/AAC.45.8.2316-2323.2001.
3
Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections.伐昔洛韦：关于其在单纯疱疹病毒和巨细胞病毒感染管理中的长期效用综述。
Drugs. 2000 Apr;59(4):839-63. doi: 10.2165/00003495-200059040-00013.
4
Effects of famciclovir and valacyclovir on herpes simplex virus type 1 infection, latency, and reactivation in mice: how dissimilar are study results?泛昔洛韦和伐昔洛韦对小鼠1型单纯疱疹病毒感染、潜伏及再激活的影响：研究结果有多大差异？
J Infect Dis. 2000 Apr;181(4):1517-8. doi: 10.1086/315408.
5
The impact of the herpetic eye disease studies on the management of herpes simplex virus ocular infections.疱疹性眼病研究对单纯疱疹病毒眼部感染管理的影响。
Curr Opin Ophthalmol. 1999 Aug;10(4):230-3. doi: 10.1097/00055735-199908000-00002.
6
The comparative effects of famciclovir and valacyclovir on herpes simplex virus type 1 infection, latency, and reactivation in mice.泛昔洛韦和伐昔洛韦对小鼠1型单纯疱疹病毒感染、潜伏及再激活的比较效应
J Infect Dis. 1999 Sep;180(3):594-9. doi: 10.1086/314962.
7
Bypass of lethality with mosaic mice generated by Cre-loxP-mediated recombination.利用Cre-loxP介导的重组产生的嵌合小鼠绕过致死性。
Curr Biol. 1996 Oct 1;6(10):1307-16. doi: 10.1016/s0960-9822(02)70717-3.
8
Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency.泛昔洛韦和伐昔洛韦对单纯疱疹病毒在小鼠感染模型（包括潜伏再激活）发病机制中的不同作用。
J Infect Dis. 1996 Feb;173(2):291-9. doi: 10.1093/infdis/173.2.291.
9
Species differences in the disposition of acyclovir.阿昔洛韦处置过程中的种属差异。
Am J Med. 1982 Jul 20;73(1A):31-5. doi: 10.1016/0002-9343(82)90059-6.
10
A quantitative study of the effects of several nucleoside analogues on established herpes encephalitis in mice.几种核苷类似物对小鼠已建立的疱疹性脑炎影响的定量研究。
J Gen Virol. 1984 Apr;65 ( Pt 4):707-19. doi: 10.1099/0022-1317-65-4-707.
Zotero 插件